934-26-9

Basic information

• Product Name: NSC68992
• Synonyms: NSC68992;6-chloro-3-hydrazineylpyridazin-4-amine
• CAS NO: 934-26-9
• Molecular Formula: C4H6ClN5
• Molecular Weight: 159.58
• Mol File: 934-26-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 190 °C(Solv: ethanol (64-17-5))
• Boiling Point: 449.2°C at 760 mmHg
• Flash Point: 225.5°C
• Appearance: /
• Density: 1.649g/cm³
• Vapor Pressure: 2.92E-08mmHg at 25°C
• Refractive Index: 1.766
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.96±0.40(Predicted)
• CAS DataBase Reference: NSC68992(CAS DataBase Reference)
• NIST Chemistry Reference: NSC68992(934-26-9)
• EPA Substance Registry System: NSC68992(934-26-9)

Safety Data

• Hazardous Substances Data: 934-26-9(Hazardous Substances Data)

Usage

Uses

6-Chloro-3-hydrazinylpyridazin-4-amine is used to synthesize heterocyclic ring system as potential purine antagonist.

InChI:InChI=1/C4H6ClN5/c5-3-1-2(6)4(8-7)10-9-3/h1H,7H2,(H2,6,9)(H,8,10)

Upstream product

• 823-58-5 3,6-dichloropyridazin-4-amine 

Downstream Products

• 53085-52-2 6-chloro-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-amine 
• 6698-57-3 6-chloro-1,2,4-triazolo<4,3-b>pyridazin-8-amine 
• 29049-45-4 3-chloro-5-aminopyridazine 

Relevant articles and documents

GPR139 RECEPTOR MODULATORS

Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

Chemical Proteomic Profiling of Bromodomains Enables the Wide-Spectrum Evaluation of Bromodomain Inhibitors in Living Cells

Bromodomains, epigenetic "readers" of lysine acetylation marks, exist in different nuclear proteins with diverse biological functions in chromatin biology. Malfunctions of bromodomains are associated with the pathogenesis of human diseases, such as cancer. Bromodomains have therefore emerged as therapeutic targets for drug discovery. Given the high structural similarity of bromodomains, a critical step in the development of bromodomain inhibitors is the evaluation of their selectivity to avoid off-target effects. While numerous bromodomain inhibitors have been identified, new methods to evaluate the inhibitor selectivity toward endogenous bromodomains in living cells remain needed. Here we report the development of a photoaffinity probe, photo-bromosporine (photo-BS), that enables the wide-spectrum profiling of bromodomain inhibitors in living cells. Photo-BS allowed light-induced cross-linking of recombinant bromodomains and endogenous bromodomain-containing proteins (BCPs) both in vitro and in living cells. The photo-BS-induced labeling of the bromodomains was selectively competed by the corresponding bromodomain inhibitors. Proteomics analysis revealed that photo-BS captured 28 out of the 42 known BCPs from the living cells. Assessment of the two bromodomain inhibitors, bromosporine and GSK6853, resulted in the identification of known as well as previously uncharacterized bromodomain targets. Collectively, we established a chemical proteomics platform to comprehensively evaluate bromodomain inhibitors in terms of their selectivity against endogenous BCPs in living cells.

Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.